港股又一黑马丨觅瑞上市背后，藏着国产早筛全球化的终极答案

Group 1: Industry Overview - The global cancer early screening market has surpassed $50 billion and is growing at an annual rate of 18% [1] - Despite advanced technology, over 80% of domestic early screening products in China remain confined to the local market due to stringent regulations and high approval barriers in international markets [1] - The European IVDR regulations and the U.S. FDA's classification of early screening products as high-risk Class III devices contribute to the challenges faced by Chinese companies in entering international markets [1] Group 2: Company Profile - Mirxes - Mirxes, established in 2014 and headquartered in Singapore, specializes in RNA technology and aims to provide disease screening solutions globally [3] - Its core product, GASTROClear™, is the first and only approved molecular diagnostic IVD product for gastric cancer screening, having received various international certifications including EU CE and U.S. FDA breakthrough device designation [3][6] - The company plans to leverage its successful IPO on the Hong Kong Stock Exchange to enhance its technology development, market expansion, and international collaborations [5] Group 3: Strategic Initiatives - Post-IPO, Mirxes aims to invest in research for new cancer screening technologies and explore multi-cancer screening products to improve accuracy and detection range [5][6] - The company intends to attract top global research talent and deepen collaborations with international medical institutions to advance its miRNA technology in liquid biopsy applications [6] - Mirxes' strategy includes forming partnerships with renowned pharmaceutical companies and research institutions to enhance its technical capabilities and market competitiveness [6]